Tevogen Q2 FY26 net loss widens to $5.76 million; operating loss rises to $5.66 million
TVGN•Quarterly loss and expense trends
- Tevogen posted a Q2 net loss of $5.76 million, widening from $5.5 million a year earlier.
- Operating loss widened to $5.66 million from $5.44 million, with R&D expense rising 21.58% to $3.28 million.
- G&A expense fell 13.29% to $2.38 million, due to lower legal and professional fees and stock-based compensation.
- Cash totaled $1.1 million at June 30, 2026; management said liquidity covers at least 12 months with loan capacity and committed grants.
Related News
Nuo Therapeutics Q2 FY26 revenue more than doubles to $1.77 million; gross profit climbs to $1.17 million
AURX•
Plum Acquisition III deregisters units, Class A shares and redeemable warrants under Exchange Act
PLMJF•
